CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial

Breast Cancer Research and Treatment

Volumn 140, Issue 2, 2013, Pages 363-373

  Dezentje V O ^a   Van Schaik, R H N ^b   Vletter Bogaartz, J M ^a   Van Der Straaten, T ^a   Wessels, J A M ^a   Kranenbarg, E M K ^a   Berns, E M ^b   Seynaeve, C ^b   Putter, H ^a   Van De Velde, C J H ^a   Nortier, J W R ^a   Gelderblom, H ^a   Guchelaar, H J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CYP2D6; Early breast cancer; Pharmacogenetics; Tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; EXEMESTANE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B15; TAMOXIFEN; UNCLASSIFIED DRUG; AROMATASE INHIBITOR; ESTROGEN RECEPTOR ALPHA, HUMAN;

ADJUVANT THERAPY; ADULT; AGED; ALLELE; BREAST CANCER; CANCER PATIENT; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; CYP2D6 GENE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA FLANKING REGION; DRUG EFFICACY; DRUG METABOLISM; EARLY CANCER; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; NETHERLANDS; PHARMACOGENETICS; PHENOTYPE; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYTOCHROME P-450 CYP2D6; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENOTYPE; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; TAMOXIFEN;

EID: 84881474045     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2619-6     Document Type: Conference Paper

References (40)

1. Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075
2. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764
3. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39
4. Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471-478
5. Lim YC, Li L, Desta Z, Zhao Q, Rae JM, Flockhart DA, et al. (2006) Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 318:503-512
6. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC (2009) The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69:1722-1727
7. Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, et al. (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708-717. doi: 10.1038/clpt.2011.27
8. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318
9. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429-1436
10. Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H (2009) Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 15:15-21
11. Lash TL, Lien EA, Sorensen HT, Hamilton-Dutoit S (2009) Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 10:825-833
12. Dezentje VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, et al. (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28:2423-2429
13. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693
14. Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, et al. (2010) CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 12:R64
15. Goetz M, Berry D, Klein T, International Tamoxifen Pharmacogenomics Consortium (2009) Adjuvant tamoxifen treatment outcome according to cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer: findings from the International Tamoxifen Pharmacogenomics Consortium. Cancer Res 69:33
16. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, et al. (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104:441-451. doi: 10.1093/jnci/djs125
17. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, et al. (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452-460. doi: 10.1093/jnci/djs126
18. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, et al. (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89:718-725. doi: 10.1038/clpt.2011.32
19. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, et al. (2008) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19:56-61. doi: 10.1093/annonc/mdm434
20. Nishiyama T, Ogura K, Nakano H, Ohnuma T, Kaku T, Hiratsuka A, et al. (2002) Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63:1817-1830
21. Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet R, Chen G, et al. (2007) Glucuronidation of active tamoxifen metabolites by the human UDP-glucuronosyltransferases (UGTs). Drug Metab Dispos 35:2006-2014
22. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 104:1264-1268. doi: 10.1093/jnci/djs304
23. Pharoah PD, Abraham J, Caldas C (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:1263-1264. doi: 10.1093/jnci/djs312
24. Stanton V Jr (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 104:1265-1266. doi: 10.1093/jnci/djs305
25. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ (2012) Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet 14:23-34. doi: 10.1038/nrg3352
26. Castells A, Gusella JF, Ramesh V, Rustgi AK (2000) A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res 60:2836-2839
27. van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, et al. (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377:321-331
28. Baak-Pablo R, Dezentje V, Guchelaar HJ, van der Straaten T (2010) Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. J Mol Diagn 12:746-749
29. Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Rosenberg CL, Sorensen HT, et al. (2010) Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clin Epidemiol 2:241-246. doi: 10.2147/CLEP.S13811
30. Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, et al. (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9:258-264
31. Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, et al. (2010) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125:279-287
32. Kiyotani K, Mushiroda T, Hosono N, Tsunoda T, Kubo M, Aki F, et al. (2010) Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet Genomics 20:565-568
33. Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, von Moltke LL, et al. (2004) UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther 310:656-665
34. Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Soiland H, Gjerde J, et al. (2011) Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiol Biomarkers Prev 20:1937-1943
35. Jin Y, Hayes DF, Li L, Robarge JD, Skaar TC, Philips S, et al. (2008) Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol 26:5849-5854
36. Onitilo AA, McCarty CA, Wilke RA, Glurich I, Engel JM, Flockhart DA, et al. (2009) Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat 115:643-650
37. Hayes DF, Skaar TC, Rae JM, Henry NL, Nguyen AT, Stearns V, et al. (2010) Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results. Clin Pharmacol Ther 88:626-629. doi: 10.1038/clpt.2010.143
38. van Duijnhoven FJ, Peeters PH, Warren RM, Bingham SA, Uitterlinden AG, van Noord PA, et al. (2006) Influence of estrogen receptor alpha and progesterone receptor polymorphisms on the effects of hormone therapy on mammographic density. Cancer Epidemiol Biomarkers Prev 15:462-467
39. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW (2004) Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96:621-628
40. Grabinski JL, Chisholm G, Smith LS, Drengler RL, Kalter S, Rodriguez G et al. (2008) ER alpha genotypes and breast cancer recurrence. J Clin Oncol 26(15S):501